H. Jack West, MD: There was a trial called SQUIRE that looked at a combination of cisplatin and gemcitabine with or without necitumumab, which is an anti-EGFR monoclonal antibody. This demonstrated a modest but statistically significant overall survival benefit in this challenging population with advanced squamous non—small cell lung cancer, where we really haven’t had a targeted therapy available, certainly in the first-line setting. This trial has led to the FDA approval of necitumumab.
Its use in the clinic has been limited. I think that’s just been due to a question of what we might perceive as statistical significance versus clinical significance when you’re talking about an improvement in median overall survival of less than a couple of months, adding some potential toxicities such as rash and diarrhea that can accompany anti-EGFR agents. And so, it is an option, though I don’t think it is going to be a widely practiced one. Certainly, history up until now has demonstrated that it has not been widely adopted.
It’s going to be challenging as we see more options emerge in the first-line setting for patients with squamous non—small cell lung cancer—particularly several positive trials for chemotherapy in combination with immunotherapy in the first-line setting, or immunotherapy as monotherapy for the subset of patients with historically high PD-L1 expression, and even just a 1% cutoff, as was demonstrated in a positive trial, KEYNOTE-042. So, it’s an option, though I think it’s going to be a challenged option that, historically, has not been widely used.
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks
April 30th 2024Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.
Read More